Ian M. Burr Division of Pediatric Endocrinology and Diabetes Archive — Page 2 of 3

William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

Top-down view of socked feet standing on a glass bathroom scale against a blue background; the display is blank or unreadable.
February 10, 2022

New insights into hypothalamic obesity

A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report.

Illustration of red blood cells and several white blood cells suspended in a red bloodstream.
September 16, 2021

‘Pre-conditioning’ restores immune tolerance

A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.

Team members involved in the study include, from left, Melissa Hilmes, MD, Daniel Moore, MD, PhD, Alvin Powers, MD, Jon Williams, PhD, and Jack Virostko, PhD. (photo by Jessica Kimber)
August 27, 2021

Study proves standardized protocol can support reliable MRI use for multisite pancreatic research

Researchers with the Vanderbilt Diabetes Research and Training Center (DRTC) at Vanderbilt University Medical Center led a multisite study which has demonstrated that, when controlled and standardized, quantitative magnetic resonance imaging (MRI) of the pancreas is highly reproducible when using different MRI hardware and software at different geographic locations.

A transparent medical syringe is embedded diagonally in the bullseye of a black-and-yellow dartboard. Measurement markings are visible on the syringe.
November 3, 2020

New treatment for a rare obesity

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.

June 9, 2019

Study drug delays type 1 diabetes in high risk children and adults

Drug delays onset of type 1 diabetes by two years